Glucagon-like peptide-1 (GLP‑1) receptor agonists are a class of medication used to lower blood glucose (sugar) levels in individuals with type 2 diabetes. The first GLP-1, exenatide (Byetta), was approved in 2005. Multiple GLP-1 products and formulations are now available.
The post What We’ve Learned About GLP-1 Agonists to Date appeared first on Heart Advisor.